Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Mdm2 Stories

2012-01-21 00:11:46

The expression of p53 and Mdm2 is closely related. In an article published this week in the Cancel Cell review, Robin Fahraeus and his collaborators from Inserm Unit 940 ("Therapeutic Targets for Cancer"), demonstrate that cellular response to DNA damage requires involvement from the protein kinase ATM so that Mdm2 can positively or negatively control protein p53. Much focus is placed on protein p53 in cancer research. Discovered in 1979, p53 precisely regulates cell proliferation and...

2011-12-13 07:00:00

SAN DIEGO, Dec. 13, 2011 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. announced today that two of its first-in-class agents, both inhibitors of newly-validated targets, have demonstrated encouraging activity in several preclinical models of high risk leukemias, cancers for which there are limited clinical treatment options. Dr. Ross Hannan of the Peter MacCallum Cancer Centre (PMCC), Melbourne, Australia, reported how CX-5461, a targeted inhibitor of RNA Polymerase I (Pol I),...

2011-11-07 11:53:44

Discovery generates potential for new anti-cancer therapies Researchers at the University of Southern California have identified two molecules that may be more effective cancer killers than are currently available on the market. The peptides, molecules derived from a cancer-causing virus, target an enzyme in cancerous cells that regulates a widely researched tumor suppressor protein known as p53. The peptides inhibit the enzyme, causing p53 levels in cancer cells to rise, which leads to...

2011-10-13 07:00:00

SAN DIEGO, Oct. 13, 2011 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. has advanced its targeted, non-genotoxic, activator of p53 for the treatment of leukemias, lymphomas and multiple myeloma through formal preclinical development, the Company announced today. The small molecule, CX-5461, avoids the direct DNA damaging side-effects typically seen with current p53 activating drugs by selectively inhibiting the newly-validated RNA Polymerase I (Pol I) cancer target. Upon activation the p53...

2011-07-15 14:23:16

A protein that appears to play a key role in the formation of lymphoma and other tumors by inhibiting a tumor-suppressing gene has been identified by a team of veterinary and human medicine researchers at the University of California, Davis. The researchers suggest that the newly identified protein may be a potential target for diagnosing and treating lymphoma in humans and animals. They will report their findings July 15 in the journal Genes & Development. "Results from this study...

2011-07-15 07:20:39

(Ivanhoe Newswire) "“ According to the Leukemia and Lymphoma Society, over 21,000 Americans died from lymphoma cancer last year. Lymphoma refers to a group of blood cancers that start in the lymphatic system, a network of lymph vessels and lymph nodes that play a vital role in the body's immune system. Researchers believe that a newly identified protein may be a potential target for diagnosing and treating lymphoma in humans and animals. The protein appears to play a key role in the...

2011-07-01 12:56:51

Salk Institute scientists show how regulation of a key damage response protein can make the difference between survival and death after radiation Scientists at the Salk Institute for Biological Studies have found clues to the functioning of an important damage response protein in cells. The protein, p53, can cause cells to stop dividing or even to commit suicide when they show signs of DNA damage, and it is responsible for much of the tissue destruction that follows exposure to ionizing...

2011-04-20 15:07:24

IDIBELL researchers at UB have tested this molecule antagonist of MDM2, a protein active in brain tumors Researchers of Apoptosis and Cancer Group of the Bellvitge Biomedical Research Institute (IDIBELL) have found that a small molecule, Nutlin-3a, an antagonist of MDM2 protein, stimulates the signalling pathway of another protein, p53. By this way, it induces cell death and senescence (loss of proliferative capacity) in brain cancer, a fact that slows its growth. These results open the door...

2011-04-06 22:05:06

Small-molecule MDM2 inhibitors developed at U-M show promise in multiple cancer types A study led by researchers at the University of Michigan Comprehensive Cancer Center showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects. The study, done in two mouse models of human cancer, looked at two compounds designed to activate a protein that kills cancer cells. The protein, p53, is inactivated in a significant number of human cancers. In some...

2011-03-29 16:57:41

Protein aggregation, generally associated with Alzheimer's and mad cow disease, turns out to play a significant role in cancer. In a paper published in Nature Chemical Biology, Frederic Rousseau and Joost Schymkowitz of VIB, K.U.Leuven and Vrije Universiteit Brussel describe that certain mutations of p53, an important tumor suppressor, cause the protein to misfold in a way that the proteins start to aggregate. This not only disrupts the protective function of normal p53, but of other related...